SOUND Biopharmaceuticals is a biopharmaceutical start-up that focuses on innovation of next-generation antibody drug. SOUND was co-founded by Nobel Prize-winning team whose aim is to foster innovative and life-saving drugs worldwide. Additionally, company have created several advanced core technology platforms such as monoclonal antibody screening, antibody humanization, molecular activity detection and optimization, protein production, purification, and bi-specific nanoantibodies. With exceptional scientific research and innovative drug development capabilities, the company has created a diverse pipeline of original biomacromolecular drug products that have great market potential and can meet unmet clinical needs.